Reset Font to Default Medium Font Larger Font

Menactra Antitrust Litigation Settlement Website

Update: Distribution of the Court-approved award payments to claimants who made valid claims took place on November 2, 2018. 

Please visit the visit the Commonly Asked Questions page of this website for further information regarding distribution. 

The Court has approved a proposed $61.5 million settlement in a class action lawsuit called Castro, et al. v. Sanofi Pasteur Inc., No. 11-7178 pending in the U.S. District Court for the District of New Jersey. The Settlement Fund will pay valid claims of members of the Class who purchased Menactra directly from Sanofi Pasteur Inc. from March 1, 2010 through and including December 31, 2014.

The lawsuit, brought by three pediatric physician practices, claimed that physicians, medical practices, vaccine distributors/wholesalers, and health systems who bought Menactra directly from Sanofi paid higher prices than they should have for quadrivalent meningococcal vaccines (“MCV4 Vaccines”), which inoculate against four strains of bacterial meningitis. The lawsuit alleged that the higher prices resulted from Sanofi engaging in anticompetitive conduct. Sanofi denies these allegations. The Court has not decided who is right because the parties have agreed to a settlement. 

On October 20, 2017, the Court approved the Settlement and authorized Claim Forms to be mailed to Class Members with eligible purchases.  Claim Forms were mailed to these Class Members on November 16, 2017.  Claims must be submitted online or by mail postmarked by the extended deadline of February 20, 2018.  Late claims are no longer being accepted.

Continue to visit this site, or call the Settlement Administrator at 1-866-216-0279, to obtain updates regarding the Settlement, or with questions.  You may also visit the Commonly Asked Questions page of this website for further information.  

Link to

View the Privacy Policy